Vertex Pharmaceuticals Rating Increased to Buy at Brean Murray Carret & Co. (VRTX)

By admin | 6 years ago

Vertex Pharmaceuticals (NASDAQ: VRTX) was upgraded by equities research analysts at Brean Murray Carret & Co. to a “buy” rating in a research note issued to investors on Monday.

A number of other firms have also recently commented on VRTX. Analysts at Brean Murray upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Monday. Separately, analysts at JPMorgan Chase (NYSE: JPM) reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note to investors on Monday. Finally, analysts at JMP Securities upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Monday.

Shares of Vertex Pharmaceuticals traded up 2.72% during mid-day trading on Monday, hitting $59.70. Vertex Pharmaceuticals has a 52 week low of $26.50 and a 52 week high of $58.87. The company has a market cap of $12.589 billion and a P/E ratio of 41.34.

Vertex Pharmaceuticals last announced its earnings results on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $0.72 earnings per share next quarter.

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

About the author